Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Alaska Women's Cancer Care — Anchorage, Alaska
- Banner University Medical Center - Tucson — Tucson, Arizona
+ 400 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07198074
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
+ 186 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Locations: - The University of Alabama at Birmingham — Birmingham, Alabama
- Honor Health — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 81 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…
Sponsor: AstraZeneca
NCT ID: NCT07044336
Locations: - Research Site — Tucson, Arizona
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
+ 63 more sites in the U.S.
Phase 3 Recruiting Industry
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…
Sponsor: AstraZeneca
NCT ID: NCT06989112
Locations: - Research Site — Tucson, Arizona
- Research Site — Little Rock, Arkansas
- Research Site — Duarte, California
+ 57 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Locations: - George Washington University Medical Center — Washington D.C., District of Columbia
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
+ 52 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicate…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06952504
Locations: - University of South Alabama, Mitchell Cancer Institute ( Site 6033) — Mobile, Alabama
- Alaska Women's Cancer Care ( Site 6036) — Anchorage, Alaska
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) — Orange, California
+ 41 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endomet…
Sponsor: Genmab
NCT ID: NCT07166094
Locations: - MedStar Washington Hospital — Washington D.C., District of Columbia
- SMH - Sarasota - Main Campus — Sarasota, Florida
- Women's Care - 9th Ave — St. Petersburg, Florida
+ 40 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part…
Sponsor: Kartos Therapeutics, Inc.
NCT ID: NCT05797831
Locations: - Kaiser Permanente Center — Vallejo, California
- Northside Hospital — Atlanta, Georgia
- St. Joseph — Savannah, Georgia
+ 16 more sites in the U.S.
Phase 3 Recruiting Industry
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how…
Sponsor: BioNTech SE
NCT ID: NCT06340568
Locations: - MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Broward Health Medical Center — Fort Lauderdale, Florida
- The Center of Hope Reno — Reno, Nevada
+ 4 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course va…
Sponsor: University of Utah
NCT ID: NCT03422198
Locations: - Stanford Cancer Center — Palo Alto, California
- Loyola University Medical Center — Maywood, Illinois
- MD Anderson — Houston, Texas
+ 2 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachyther…
Sponsor: Kara Romano, MD
NCT ID: NCT03785288
Locations: - University of Maryland Medical Center (UMMC) — Baltimore, Maryland
- SUNY Upstate Medical University — Syracuse, New York
- University of Virginia — Charlottesville, Virginia